NTAGI panel reviews data for Corbevax as booster for adults who got Covishield, Covaxin shots – ET HealthWorld

New Delhi: The National Technical Advisory Group on Immunisation’s Covid working group has reviewed the data of Biological E’s Corbevax to allow it as booster for those aged 18 and above fully vaccinated with Covishield or Covaxin, official sources said Thursday. No recommendation has yet been made in this matter by the NTAGI panel in its meeting on Wednesday. The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India’s first indigenously developed RBD protein subunit vaccine, Corbevax,…

Read More

New qHPV vaccine: Dawn for cervical cancer prevention? – ET HealthWorld

Mumbai: The Drug Controller General of India (DCGI) has approved the first Indian HPV vaccine to prevent cervical cancer. The vaccine Cervavac will be manufactured by the Serum Institute of India (SII) and is the nation’s first quadrivalent human papillomavirus vaccine (qHPV) vaccine. Cervical cancer is a common sexually transmitted infection. Long-lasting infection with certain types of HPV is the main cause of cervical cancer. It is the second most common cancer among Indian women constituting almost 1/5th of their cancer burden. Over 95 per cent of cervical cancer cases…

Read More

NTAGI to discuss data of Gennova pharmaceuticals’ indigenous mRNA vaccine – ET HealthWorld

New Delhi: The National Technical Advisory Group on Immunisation (NTAGI‘s) Covid working group is expected to conduct a meeting soon to discuss India‘s first mRNA vaccine against COVID and Biological E’s Corbevax Booster dose for Covishield and Covaxin beneficiaries, said the sources on Monday. Recently, the Drugs Controller General of India (DCGI) approved 2 dose mRNA vaccine of Gennova Biopharmaceuticals for COVID for restricted use in emergency situations for the above-18-years age group. It is the first time ever that this vaccine is stable for storage at 2 to 8…

Read More

SII urges MoHFW to include Cy-Tb injection in national TB elimination programme – ET HealthWorld

New Delhi: Serum Institute has requested the Union health ministry for inclusion of their Cy-Tb injection for detection of Latent-TB in the National TB Elimination Programme (NTEP) to support TB free-India by 2025, official sources said on Monday. The Serum Institute had recently informed the ministry that the firm would provide Cy-Tb injection at Rs 350 plus GST per dose, an official source stated. The letter for the inclusion of Cy-Tb was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII. The Cy-Tb injection was granted market…

Read More

Gennova Biopharmaceuticals mRNA COVID-19 vaccine receives EUA from DCGI – ET HealthWorld

Pune, India, June 29, 2022: Gennova Biopharmaceuticals announced that its mRNA vaccine – GEMCOVAC-19 – against COVID 19 received the emergency use authorisation (EUA) from the office of the Drugs Controller General of India (DCGI). GEMCOVAC-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world. These vaccines are highly efficacious because of their inherent capacity of being translated into the protein structure inside the cell cytoplasm. mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in…

Read More

NTAGI recommends vaccination against cervical cancer and Typhoid: Sources – ET HealthWorld

New Delhi: The government advisory panel NTAGI on Tuesday is learnt to have recommended vaccination against cervical cancer and typhoid after examining the data in this regard. The separately constituted HPV working group of NTAGI had on June 8 reviewed the clinical trial data and the usefulness of Serum Institute’s indigenously-developed and India‘s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer for inclusion in the National Immunization program, sources said. According to official sources, the subject expert committee of Central Drugs Standard Control Organisation (CDSCO) had on June 15…

Read More

India’s first mRNA COVID-19 vaccine to get Emergency Use Authorisation soon – ET HealthWorld

New Delhi: The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India‘s first mRNA COVID-19 vaccine, sources told on Tuesday. The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova‘s mRNA vaccine any time soon. The SEC under India’s drug regulator found data submitted by Gennova Biopharmaceuticals satisfactory in the Friday meeting, people in the know told ANI. The company submitted data in April and provided additional data in May. Earlier in May, Gennova had released…

Read More

Govt panel recommends emergency approval for SII’s Covovax for 7-11 year olds – ET HealthWorld

New Delhi: An expert panel of India‘s central drug authority on Friday recommended granting emergency use authorisation to Serum Institute’s Covovax for children aged 7 to 11 years, official sources said. The recommendation has been sent to Drugs Controller General of India (DCGI) for final approval. The application for emergency use authorisation was submitted by Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) on March 16. “The Subject Expert Committee (SEC) on COVID-19 of the CDSCO deliberated on the EUA application of SII and…

Read More

Biological E gets WHO nod to be additional facility for production of Johnson & Johnson Covid vaccine – ET HealthWorld

New Delhi: Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine. “Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing,” the US embassy in India said in a tweet on Wednesday. India’s first indigenously developed RBD protein subunit vaccine, Biological E’s Corbevax, is currently being used to inoculate children in the age group…

Read More

DCGI recommends Serum Institute’s qHPV vaccine against cervical cancer – ET HealthWorld

New Delhi: The Drugs Controller General of India’s (DCGI) Subject Expert Committee on Wednesday recommended Serum Institute‘s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients. “An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India‘s indigenously-developed India’s first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer,” a source said. The vaccine has been recommended for cervical cancer patients – those above 9 years to 26 years of age – for both male and female. According to the…

Read More